New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation: reflections on the evidence

Christian Frerker; Nicole Karam; Rebecca T. Hahn; Holger Thiele; Gregg W. Stone; Hendrik Treede; Jörg Hausleiter

doi:10.1002/ejhf.2497

New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation: reflections on the evidence

Christian Frerker, Nicole Karam, Rebecca T. Hahn, Holger Thiele, Gregg W. Stone, Hendrik Treede, Jörg Hausleiter

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	746-749
Number of pages	4
Journal	European Journal of Heart Failure
Volume	24
Issue number	5
DOIs	https://doi.org/10.1002/ejhf.2497
State	Published - May 2022

Access to Document

10.1002/ejhf.2497

Cite this

@article{f5cce07d036c4ff5b4627e31c13c1dfc,

title = "New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation: reflections on the evidence",

author = "Christian Frerker and Nicole Karam and Hahn, {Rebecca T.} and Holger Thiele and Stone, {Gregg W.} and Hendrik Treede and J{\"o}rg Hausleiter",

note = "Funding Information: C.F. reports grants and personal fees from Abbott Vascular, personal fees from Edwards Lifesciences, outside the submitted work. N.K. reports personal fees from Edwards Lifesciences, Medtronic Inc, Abbott Vascular, outside the submitted work. R.T.H. reports speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; she has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic and Novartis; she has stock options with Navigate; and is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry‐sponsored trials, for which she receives no direct industry compensation. H.T. has nothing to disclose. G.W.S. reports personal fees from Cook, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V‐wave, Abiomed, Shockwave, Vectorious, Cardiomech, Elucid Bio, Occlutech, Infraredx, CorFlow, Apollo Therapeutics, Impulse Dynamics Amgen, other from Applied Therapeutics, Xenter, Biostar family of funds, Aria, Cardiac Success, Cagent, SpectraWave, Orchestra Biomed, personal fees and other from Valfix, Ancora, outside the submitted work; and institutional conflicts: Mount Sinai receives research grants from Abbott, Shockwave, Vascular Dynamics, Phillips, Cardiovascular Systems Inc., Biosense Webster, Bioventrix, V‐wave, Phillips. Dr. Stone's daughter is an employee at Medtronic. H.T. reports grants and personal fees from Abbott Vascular and Edwards Lifesciences outside the submitted work. J.H. reports grants and personal fees from Abbott Vascular and Edwards Lifesciences, outside the submitted work. Conflict of interest:",

year = "2022",

month = may,

doi = "10.1002/ejhf.2497",

language = "English",

volume = "24",

pages = "746--749",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation

T2 - reflections on the evidence

AU - Frerker, Christian

AU - Karam, Nicole

AU - Hahn, Rebecca T.

AU - Thiele, Holger

AU - Stone, Gregg W.

AU - Treede, Hendrik

AU - Hausleiter, Jörg

N1 - Funding Information: C.F. reports grants and personal fees from Abbott Vascular, personal fees from Edwards Lifesciences, outside the submitted work. N.K. reports personal fees from Edwards Lifesciences, Medtronic Inc, Abbott Vascular, outside the submitted work. R.T.H. reports speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; she has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic and Novartis; she has stock options with Navigate; and is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry‐sponsored trials, for which she receives no direct industry compensation. H.T. has nothing to disclose. G.W.S. reports personal fees from Cook, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V‐wave, Abiomed, Shockwave, Vectorious, Cardiomech, Elucid Bio, Occlutech, Infraredx, CorFlow, Apollo Therapeutics, Impulse Dynamics Amgen, other from Applied Therapeutics, Xenter, Biostar family of funds, Aria, Cardiac Success, Cagent, SpectraWave, Orchestra Biomed, personal fees and other from Valfix, Ancora, outside the submitted work; and institutional conflicts: Mount Sinai receives research grants from Abbott, Shockwave, Vascular Dynamics, Phillips, Cardiovascular Systems Inc., Biosense Webster, Bioventrix, V‐wave, Phillips. Dr. Stone's daughter is an employee at Medtronic. H.T. reports grants and personal fees from Abbott Vascular and Edwards Lifesciences outside the submitted work. J.H. reports grants and personal fees from Abbott Vascular and Edwards Lifesciences, outside the submitted work. Conflict of interest:

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85130457040&partnerID=8YFLogxK

U2 - 10.1002/ejhf.2497

DO - 10.1002/ejhf.2497

M3 - Comment/debate

C2 - 35385192

AN - SCOPUS:85130457040

SN - 1388-9842

VL - 24

SP - 746

EP - 749

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 5

ER -